A clinical study of TNG462 in combination with standard of care chemotherapy for NSCLC and pancreatic cancer
Latest Information Update: 17 Nov 2024
Price :
$35 *
At a glance
- Drugs TNG 462 (Primary) ; Antineoplastics
- Indications Non-small cell lung cancer; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- 17 Nov 2024 New trial record
- 06 Nov 2024 According to Tango Therapeutics media release, the company is initiating conversations with the FDA in preparation for multiple registrational studies.
- 06 Nov 2024 According to Tango Therapeutics media release, the company is planning this study as potential paths to approval in the first line setting.